Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 10/2012

01-10-2012 | Position Paper

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges

Authors: D. Bauer, J. Krege, N. Lane, E. Leary, C. Libanati, P. Miller, G. Myers, S. Silverman, H. W. Vesper, D. Lee, M. Payette, S. Randall

Published in: Osteoporosis International | Issue 10/2012

Login to get access

Abstract

Summary

This position paper reviews how the National Bone Health Alliance (NBHA) will execute a project to help assure health professionals of the clinical utility of bone turnover markers; the current clinical approaches concerning osteoporosis and the status and use of bone turnover markers in the USA; the rationale for focusing this effort around two specific bone turnover markers; the need to standardize bone marker sample collection procedures, reference ranges, and bone turnover marker assays in clinical laboratories; and the importance of harmonization for future research of bone turnover markers.

Introduction

Osteoporosis is a major global health problem, with the prevalence and incidence of osteoporosis for at-risk populations estimated to be 44 million Americans. The potential of bone markers as an additional tool for health care professionals to improve patient outcomes and impact morbidity and mortality is crucial in providing better health care and addressing rising health care costs. This need to advance the field of bone turnover markers has been recognized by a number of organizations, including the International Osteoporosis Foundation (IOF), National Osteoporosis Foundation, International Federation of Clinical Chemistry, and Laboratory Medicine (IFCC), and the NBHA.

Methods

This position paper elucidates how this project will standardize bone turnover marker sample collection procedures in the USA, establish a USA reference range for one bone formation (serum procollagen type I N propeptide, s-PINP) and one bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) marker, and standardize bone turnover marker assays used in clinical laboratories. This effort will allow clinicians from the USA to have confidence in their use of bone turnover markers to help monitor osteoporosis treatment and assess future fracture risk. This project builds on the recommendations of the IOF/IFCC Bone Marker Standards Working Group by developing USA reference standards for s-PINP and s-CTX, the markers identified as most promising for use as reference markers.

Results

The goals of this project will be realized through the NBHA and will include its governmental, academic, for-profit, and non-profit sector stakeholders as well as major academic and commercial laboratories. Upon completion, a parallel effort will be pursued to make bone turnover marker measurements reliable and accepted by all health care professionals for facilitating treatment decisions and ultimately be reimbursed by all health insurance payers.

Conclusions

Successful completion of this project will help assure health professionals from the USA of the clinical utility of bone turnover markers and ties in with the parallel effort of the IOF/IFCC to develop worldwide bone turnover reference ranges.
Literature
1.
NOF (2010) NOF clinician’s guide to prevention and treatment of osteoporosis. NOF, Washington
2.
Schafer AL L, Vittinghoff E, Ramachandran R, Mahmoud N, Bauer DC (2010) Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int 21:439–455PubMedCrossRef
3.
Vasikaran S, Eastell R, Bruyere O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis Int 22(2):391–420CrossRef
4.
Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type 1 collagen (serum s-CTX): effects of gender, age, menopausal status, posture, daylight, serum cortisol and fasting. Bone 31:57–61PubMedCrossRef
5.
Clowes JA, Hannon RA, Yap TA, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886–890PubMedCrossRef
6.
Rifai N, Cooper GR, Brown WV, Friedewald W, Havel RJ, Myers GL, Warnick GR (2004) Clinical chemistry journal has contributed to progress in lipid and lipoprotein testing for fifty years. Clin Chem 50:1861–1870PubMedCrossRef
7.
Little RR, Rohlfing CL, Sacks DB, National Glycohemoglobin Standardization Program (NGSP) Steering Committee (2011) Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 57:205–214PubMedCrossRef
8.
9.
Miller WG, Myers GL, Gantzer LM, Kahn SE, Schönbrunner ER, Thienpont LM, Bunk DM, Christenson RH, Eckfeldt JH, Lo SF, Nübling CM, Sturgeon CM (2011) Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 57:1108–1117CrossRef
10.
11.
12.
13.
14.
15.
Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R (2008) Establishing a reference range for bone turnover markers in young, healthy women. Bone 42:623–630PubMedCrossRef
16.
Glover S, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley J, Black D, Delmas P, Eastell R (2009) Establishing a reference interval for bone turnover markers in 637 healthy, young, pre-menopausal women from UK, France, Belgium and the USA. J Bone Miner Res 24:389–397PubMedCrossRef
17.
de Papp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz A, Chen E, Rosenberg E, Reitz RE (2007) A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 40:1222–1230PubMedCrossRef
18.
Adami S, Bianchi G, Brandi ML, Giannini S, Ortolani S, Dimunno O, Frediani B, Rossini M (2008) Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 82:341–347PubMedCrossRef
19.
Cavalier E, Delanaye P (2009) Letter to the editor: Defining a “reference population”: no easy task. JBMR 24:1638CrossRef
20.
Eastell R, Glover SJ, Gall M, Schoenborn-Kellenberger O, Garnero P, Black D (2009) Defining a “reference population”: no easy task. JBMR 24:1639CrossRef
21.
Linnet K (1987) Two-stage transformation systems for normalization of reference distributions evaluated. Vlin Vhrm 33:381–386
22.
Baim S, Miller PD (2009) Perspective: assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 24:561–573PubMedCrossRef
23.
Keaveny TM, Kopperdahl DL, Melton LJ III, Hoffman PF, Amin S, Riggs BL, Khosla S (2010) Age-dependence of femoral neck strength in white women and men. J Bone Miner Res 25(5):994–1001PubMed
24.
Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, McClung MR, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA, IOF-IFCC Bone Markers Standard Working Group (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391–420PubMedCrossRef
25.
Melton LJ III, Khosla S, Atkinson EJ, O’Fallon WM, Riggs BL (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083–1091PubMedCrossRef
26.
Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536PubMedCrossRef
27.
Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD (2005) Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20:1813–1819PubMedCrossRef
28.
Garnero P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporosis Int 11(Suppl 6):S55–S65CrossRef
29.
Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531–1538PubMedCrossRef
30.
Ivaska KK, Gerdhem P, Vaananen HK, Akesson K, Obrant KJ (2010) Bone turnover markers and prediction of fracture: a prospective follow-up study of 1,040 elderly women for a mean of 9 years. J Bone Miner Res 25:393–403PubMedCrossRef
31.
Bauer DC, Garnero P, Harrison SL, Cauley JA, Eastell R, Ensrud KE, Orwoll E (2009) Osteoporotic fractures in men (MrOs) Research Group. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOs Study. J Bone Miner Res 24(12):2032–2038PubMedCrossRef
32.
Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100–103PubMedCrossRef
33.
Recker R, Stakkestad JA, Chesnut CH III, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:89–93CrossRef
34.
Papapolpous S, Schimmer RC (2007) Changes in bone remodeling and anti-fracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 66(7):853–858
35.
Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRef
36.
Christiansen C, Riis BJ, Rodbro P (1987) Prediction of rapid bone loss in postmenopausal women. Lancet 1:1105–1108PubMedCrossRef
37.
Lenora J, Ivaska KK, Obrant KJ, Gerdhem P (2007) Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 18:1297–1305PubMedCrossRef
38.
Rogers A, Hannon RA, Eastell R (2000) Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 15:1398–1404PubMedCrossRef
39.
Greenspan SL, Resnick NM, Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762–2767PubMedCrossRef
40.
Hannon RA, Bluhmson A, Naylor KE, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy. J Bone Miner Res 13:1124–1133PubMedCrossRef
41.
Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS (2005) Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 52:667–674PubMedCrossRef
42.
Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237–244PubMedCrossRef
43.
Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–2368PubMedCrossRef
44.
Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431–1438PubMedCrossRef
45.
Greenspan SL, Rosen HN, Parker RA (2000) Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 85:3537–3540PubMedCrossRef
46.
Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051–1056PubMedCrossRef
47.
Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258PubMedCrossRef
48.
Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D et al (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344–351PubMedCrossRef
49.
Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, Bruyere O (2008) Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42:832–836PubMedCrossRef
50.
Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48:798–803PubMedCrossRef
51.
Porter D, Pienowski D, Monier-Faugere MC, Mallluche H (2012) Difference in bone quality between high versus low turnover renal osteodystrophy. JASN (in press)
52.
Nickolas T, Cremers S, Zhang A, Stein E, Cohen A, Chauncey R, Nikkel L, Liu X, Boutroy S, Yin M, Staron R, Leonard M, McMahon D, Dworakowski E, and Shane E (2012) Biochemical markers of bone turnover discriminate fracture status in patients with pre-dialysis chronic kidney disease. JASN (in press)
53.
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475PubMedCrossRef
Metadata
Title
National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges
Authors
D. Bauer
J. Krege
N. Lane
E. Leary
C. Libanati
P. Miller
G. Myers
S. Silverman
H. W. Vesper
D. Lee
M. Payette
S. Randall
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 10/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-012-2049-z

Other articles of this Issue 10/2012

Osteoporosis International 10/2012 Go to the issue

Review

Iron homeostasis in osteoporosis and its clinical implications

Original Article

Iron excess limits HHIPL-2 gene expression and decreases osteoblastic activity in human MG-63 cells

Original Article

Volumetric bone mineral density at the spine and hip in Chinese American and White women

Original Article

Growth from birth to adulthood and peak bone mass and density data from the New Delhi Birth Cohort

Original Article

Skeletal and hormonal responses to vitamin D supplementation during sunlight deprivation in Antarctic expeditioners

Original Article

Evaluation of bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT) in hemodialysis patients